ArticleJournal of general internal medicine2019
Rising Mortality Rate of Cervical Cancer in Younger Women in Urban China.
Article in Journal of general internal medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 1 synthesis or guideline pooled it, 75 citations in OpenAlex.
- The Landscape of Health Technology for Equity Deserving Groups in Rural Communities: A Systematic Review.Community health equity research & policy · 2025Pooled it
- TMEM130 promoter hypermethylation predicts tumor cell migration in cervical cancer.Journal of molecular histology · 2026Article
- Disease burden of cervical cancer in China from 1990 to 2023 and prediction of future trends.Frontiers in oncology · 2026Article
- Comparison of long-term prognoses between 3D-printed template-guided and conventional freehand interstitial brachytherapy for locally advanced cervical cancer: a single-center retrospective study.Frontiers in oncology · 2026Article
- Reproductive concerns in young women with cervical cancer: latent profiles and key influencing factors.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025Article
- Prevalence characteristics of human papillomavirus among women in Henan Province of China.Virology journal · 2025Article
- ADAMDEC1 promotes cervical squamous cell carcinoma by enhancing the JAK/STAT signaling pathway through modulation of TYMP.Naunyn-Schmiedeberg's archives of pharmacology · 2025Article
- The role of circular RNA targeting IGF2BPs in cancer-a potential target for cancer therapy.Journal of molecular medicine (Berlin, Germany) · 2024Review
- Human papilloma virus (HPV)-related information acquisition and seeking behavior among infected women: A single center cross-sectional survey in Shanghai, China.Global health & medicine · 2024Article
- MUC1 promotes cervical squamous cell carcinoma through ERK phosphorylation-mediated regulation of ITGA2/ITGA3.BMC cancer · 2024Article
- Analysis of influencing factors of HPV vaccination willingness of female sex workers in urban entertainment venues based on the IMB model in Guangxi, China.BMC women's health · 2024Article
- Decoding Fujian's cervical HPV landscape: unmasking dominance of non-16/18 HR-HPV and tailoring prevention strategies at a large scale.Frontiers in public health · 2024Article
- NR1H4-mediated circRHOBTB3 modulates the proliferation, metastasis, and Warburg effects of cervical cancer through interacting with IGF2BP3.Molecular and cellular biochemistry · 2023Article
- Clinical analysis of 312 patients with stage IB1-IIA2 cervical squamous cell carcinoma and research on the influencing factors of postoperative recurrence.BMC women's health · 2023Article
- Patient delay and related influencing factors in Chinese women under 35 years diagnosed with cervical cancer: A cross-sectional study.Asia-Pacific journal of oncology nursing · 2023Article
- Article
- Comparative cost-effectiveness of first-line pembrolizumab plus chemotherapy vs. chemotherapy alone in persistent, recurrent, or metastatic cervical cancer.Frontiers in immunology · 2023Article
- Analysis of the disease burden trend of malignant tumors of the female reproductive system in China from 2006 to 2020.BMC women's health · 2022Article
- Trends in Incidence Rates, Mortality Rates, and Age-Period-Cohort Effects of Cervical Cancer - China, 2003-2017.China CDC weekly · 2022Article
- Differences in chemotaxis of human mesenchymal stem cells and cervical cancer cells.Apoptosis : an international journal on programmed cell death · 2022Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIn recent decades, much effort has been made in China to reduce the burden of cervical cancer.
objectiveOur study's purpose was to examine trends of cervical cancer mortality in each 5-year age group for urban and rural Chinese women, respectively. DESIGNS: Retrospective analysis of cervical cancer mortality from 1987 to 2015 from the World Health Organization Cancer Mortality Database and China Health Statistical Yearbooks.
participantsChinese women. MAIN MEASURES: Trends were examined using annual percent change (APC) and average annual percent change (AAPC) via Joinpoint regression models for each 5-year age group in urban and rural areas, respectively.
resultsIn urban China, mortality rate of cervical cancer increased significantly among urban women aged 25-54 years (AAPC 2.12~5.49%), in contrast to a decline trend among urban women older than 60 years (AAPC - 3.61~- 5.35%). In rural China, cervical cancer rates declined in all age groups, but the magnitude was smaller in women aged 30-54 years (AAPC - 0.59~- 2.20%) compared to women older than 55 years (AAPC - 3.06~- 4.33%).
conclusionMortality rate of cervical cancer is rising at an alarming rate in younger women in urban China. Timely intervention is required for these vulnerable populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.